目录产品 » Anti-Palivizumab Antibody, pAb, Rabbit
Anti-Palivizumab Antibody, PAb, Rabbit

ELISA binding of Anti-Palivizumab Antibody, pAb, Rabbit (GenScript, A02064) with Palivizumab.
Coating antigen: Palivizumab, 1 µg/ml.
Anti-Palivizumab Antibody, pAb, Rabbit (GenScript, A02064) dilution start from 1,000 ng/ml.
EC50= 3.324 ng/ml.

Anti-Palivizumab Antibody, pAb, Rabbit

The product is specific for Palivizumab.
A02064
¥1980

联系我们
Specificity The product is specific for Palivizumab.
Host Species Rabbit
Immunogen Palivizumab
Conjugate Unconjugated

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.05-1 µg/ml

Form Lyophilized
Storage Buffer Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
Purification Antigen affinity purification
Isotype Rabbit IgG
Clonality Polyclonal
Note GenScript can customize this product per customer's request including product size, buffer components, etc.

  • Anti-Palivizumab Antibody, PAb, Rabbit
  • Anti-Palivizumab Antibody, PAb, Rabbit

    ELISA binding of Anti-Palivizumab Antibody, pAb, Rabbit (GenScript, A02064) with Palivizumab.
    Coating antigen: Palivizumab, 1 µg/ml.
    Anti-Palivizumab Antibody, pAb, Rabbit (GenScript, A02064) dilution start from 1,000 ng/ml.
    EC50= 3.324 ng/ml.


Target Background Palivizumab with trade name Synagis, is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa isotype monoclonal antibody. Palivizumab binds the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process.GenScript Anti-Palivizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Palivizumab.
Synonyms Rabbit polyclonal to Synagis

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


喜欢新升级的网站吗?

讨厌

不喜欢

一般

喜欢

非常喜欢

*